ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0
|
作者：
Besse, Benjamin [1 ]
Mazieres, Julien [2 ]
Ribassin-Majed, L. [3 ]
Barlesi, Fabrice [4 ]
Bennouna, Jaafar [5 ]
Gervais, Radj [6 ]
Moreau, Lionel
Berard, Henri [7 ]
Debieuvre, Didier
Molinier, Olivier [8 ]
Moro-Sibilot, Denis [9 ]
Souquet, Pierre-Jean [10 ]
Pignon, Jean-Pierre [3 ]
Amour, Elodie [11 ]
Celebic, A. [3 ]
Morin, Franck [11 ]
Milleron, Bernard [11 ]
Zalcman, Gerard [12 ]
Soria, Jean-Charles [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France
[3] Gustave Roussy, Biostat, Villejuif, France
[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[5] Inst Cancerol Ouest, Gustave Roussy, France
[6] Ctr Francois Baclesse, Caen, France
[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France
[8] Le Mans Reg Hosp, Le Mans, France
[9] Unite Oncol Thorac Pneumol, Pierre Benite, France
[10] Pneumol Hcl, Paris, France
[11] Ifct, Paris, France
[12] Caen Univ Hosp, Caen, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO08.02
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 50 条
  • [41] Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147.
    Huang, J.
    Sargent, D. J.
    Mahoney, M. R.
    Thibodeau, S. N.
    Smyrk, T. C.
    Sinicrope, F.
    Nelson, G. D.
    Alberts, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [42] Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC
    Sanborn, Rachel
    Boulmay, Brian
    Li, Rui
    Happel, Kyle
    Puri, Sachin
    Paustian, Christopher
    Dubay, Christopher
    Aung, Sandra
    Fisher, Brenda
    Bifulco, Carlo
    Bahjat, Keith
    Koguchi, Yoshinobu
    Ochoa, Augusto
    Hu, Hong-Ming
    Hilton, Traci
    Fox, Bernard
    Urbal, Walter
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S873 - S873
  • [43] A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC.
    Heymach, JV
    Johnson, BE
    Rowbottom, JA
    Fidias, P
    Lu, C
    Prager, D
    Roubec, J
    Csada, E
    Dimery, I
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 197S - 197S
  • [44] A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (I-MAT Trial)
    Xu, W.
    Poulsen, M.
    Atkinson, V.
    Fogarty, G.
    Veness, M.
    Smithers, B.
    Gyorki, D.
    Mar, V.
    Howle, J.
    Guminski, A.
    Williams, N.
    Paton, E.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 137 - 137
  • [45] Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
    Kreuter, M.
    Vansteenkiste, J.
    Fischer, J. R.
    Eberhardt, W.
    Zabeck, H.
    Kollmeier, J.
    Serke, M.
    Frickhofen, N.
    Reck, M.
    Engel-Riedel, W.
    Neumann, S.
    Thomeer, M.
    Schumann, C.
    De Leyn, P.
    Graeter, T.
    Stamatis, G.
    Zuna, I.
    Griesinger, F.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 986 - 992
  • [46] Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study
    Johnson, Melissa L.
    Strauss, James
    Patel, Manish R.
    Garon, Edward B.
    Eaton, Keith D.
    Neskorik, Tavette
    Morin, Josee
    Chao, Richard
    Halmos, Balazs
    CLINICAL LUNG CANCER, 2023, 24 (03) : 218 - 227
  • [47] Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
    Durm, G.
    Althouse, S.
    Sadiq, A.
    Jalal, S.
    Jabbour, S.
    Zon, R.
    Kloecker, G.
    Fisher, W.
    Reckamp, K.
    Kio, E.
    Langdon, R.
    Adesunloye, B.
    Gentzler, R.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S321
  • [48] A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis
    Galdermans, D.
    Driesen, P.
    Bustin, F.
    Lambrechts, M.
    Deschepper, K.
    Stappaerts, I.
    Verresen, D.
    Janssens, A.
    Germonpre, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
    Motzer, Robert J.
    Haas, Naomi B.
    Donskov, Frede
    Gross-Goupil, Marine
    Varlamov, Sergei
    Kopyltsov, Evgeny
    Lee, Jae-Lyun
    Melichar, Bohuslav
    Rini, Brian I.
    Choueiri, Toni K.
    Zemanova, Milada
    Wood, Lori A.
    Fahlenkamp, Dirk
    Reaume, Martin Neil
    Stenzl, Arnulf
    Bao, Weichao
    Aimone, Paola
    Doehn, Christian
    Russo, Paul
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
    Pennell, N. A.
    Neal, J. W.
    Govindan, R.
    Janne, P. A.
    Evans, T. L.
    Costa, D. B.
    Rosovsky, R. P. G.
    Lanuti, M.
    Azzoli, C. G.
    Sequist, L. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345